lot move part overal
bottom line report ep significantli
cs/consensu estim respect sale
also well cs/consensu respect total sale
growth driven fx price follow volum
lower expens also contribut larg bottom line beat
commentari guidanc rais non-gaap ep guidanc
vs cs/consensu estim
revenu guidanc
vs cs/consensu estim
compani comment sale guidanc increas driven favor
segment payer mix along fx movement hand fx
move increas ms expect year lower tax
rate guidanc help boost ep rais
point quarter humalog trulic
notabl beat quarter humalog growth driven price
trulic volum alimta also beat expect
potenti due increas use product combin keytruda
nsclc forteo notabl miss taltz
basaglar also light anim health sale in-
line estim consensu
confer call detail call et dial
passcod expect focu commerci dynam
around import diabet product trulic well
expect baricitinib follow mix outcom yesterday
fda advisori committe meet drug strateg review
anim busi on-going could get updat plan
busi call along greater insight new
manag team think busi develop prioriti
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
co discov develop manufactur sell
pharmaceut product human anim manufactur
distribut product facil us puerto rico
countri
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
abemaciclib olaratumab compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale trulic
olaratumab compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
us million unless otherwis state
sale
sale
us million unless otherwis state
charl martineau univers toronto compani mention price
